Opens.
Delivers.
Maintains.
- May 2013:Why Intersect ENT is an Example of Hope for the Medtech Industry
- Mar 2013:Sinus “Stent” Helps Patients Breathe Easier
- Jan 2013:Warren Man With Chronic Sinusitus Breathes Easy After Implant Surgery
- Jan 2013:Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
- May 2013:Why Intersect ENT is an Example of Hope for the Medtech Industry
- Mar 2013:Sinus “Stent” Helps Patients Breathe Easier
- Jan 2013:Warren Man With Chronic Sinusitus Breathes Easy After Implant Surgery
- Jan 2013:Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
Company
Patents
Intersect ENT is committed to developing clinically proven therapy solutions that enable ear, nose, and throat (ENT) physicians to solve clinical challenges and improve the quality of life for patients.
Innovation and creativity are driving forces for our company. Intersect ENT holds twenty issued U.S. patents and more than 75 patents and pending applications worldwide.
20 Issued U.S. Patents
US 5,897,521
US 6,543,452
US 7,544,192
US 7,547,323
US 7,662,141
US 7,662,142
US 7,686,798
US 7,691,094
US 7,713,255
US 7,951,130
US 7,951,131
US 7,951,132
US 7,951,133
US 7,951,134
US 7,951,135
US 8,025,635
US 8,109,918
US 8,277,503
US 8,277,504
US 8,337,454
Publications
Kennedy DW.
The PROPEL steroid releasing bioabsorbable implant to improve outcomes of sinus surgery.
Expert Review of Respiratory Medicine. 2012; 6(5):493-498.
Han JK, Marple BF, Smith TL et al.
Effect of steroid-releasing sinus implants on post-operative medical and surgical interventions.
Int Forum Allergy Rhinol. 2012; 2:271-279.